These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10975476)

  • 1. The six year experience of plasmapheresis in patients with myasthenia gravis.
    Chiu HC; Chen WH; Yeh JH
    Ther Apher; 2000 Aug; 4(4):291-5. PubMed ID: 10975476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis.
    Yeh JH; Chiu HC
    J Neurol; 2000 Jul; 247(7):510-3. PubMed ID: 10993491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe generalized myasthenia gravis.
    Yeh JH; Chiu HC
    J Clin Apher; 1999; 14(4):177-80. PubMed ID: 10611627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plasmapheresis in patients with myasthenia gravis].
    Konishi T
    Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal Characteristics of Immunoadsorption with the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis.
    Ohkubo A; Okado T; Sakurasawa T; Maeda T; Itagaki A; Yamamoto H; Miyamoto S; Seshima H; Kurashima N; Mori T; Iimori S; Sohara E; Rai T; Uchida S; Naito S
    Ther Apher Dial; 2019 Jun; 23(3):271-278. PubMed ID: 31025833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
    Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
    Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review.
    Bennani HN; Lagrange E; Noble J; Malvezzi P; Motte L; Chevallier E; Rostaing L; Jouve T
    J Clin Apher; 2021 Jun; 36(3):348-363. PubMed ID: 33349954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
    Köhler W; Bucka C; Klingel R
    J Clin Apher; 2011 Dec; 26(6):347-55. PubMed ID: 22095647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience in the treatment of myasthenia gravis with double filtration plasmapheresis.
    Chuang YC; Lee CT; Chen JB; Chee EC
    Chang Gung Med J; 2000 Feb; 23(2):80-6. PubMed ID: 10835802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column].
    Yeh JH; Chiu HC
    J Microbiol Immunol Infect; 1999 Jun; 32(2):121-5. PubMed ID: 11565565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule.
    Yeh JH; Chiu HC
    Acta Neurol Scand; 1999 Mar; 99(3):147-51. PubMed ID: 10100957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double filtration plasmapheresis in myasthenia gravis--analysis of clinical efficacy and prognostic parameters.
    Yeh JH; Chiu HC
    Acta Neurol Scand; 1999 Nov; 100(5):305-9. PubMed ID: 10536917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of clinical effects between plasma adsorption and double filtration plasmapheresis in patients with myasthenia gravis.
    Okada H; Moriwaki K; Sugahara S; Nakamoto H; Hosokawa T; Hamaguchi K; Suzuki H
    Ther Apher; 1997 Nov; 1(4):343-7. PubMed ID: 10225728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmapheresis in the treatment of myasthenia gravis.
    Lenzhofer R; Graninger W; Dittrich C; Mamoli B; Zeitlhofer J; Pateisky K
    Wien Klin Wochenschr; 1983 Apr; 95(8):266-71. PubMed ID: 6603717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic apheresis in myasthenia gravis.
    Batocchi AP; Evoli A; Di Schino C; Tonali P
    Ther Apher; 2000 Aug; 4(4):275-9. PubMed ID: 10975473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal of antiacetylcholine receptor antibodies by protein-A immunoadsorption in myasthenia gravis.
    Berta E; Confalonieri P; Simoncini O; Bernardi G; Busnach G; Mantegazza R; Cornelio F; Antozzi C
    Int J Artif Organs; 1994 Nov; 17(11):603-8. PubMed ID: 7744521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen reconstitution after therapeutic apheresis: Comparison of double-filtration plasmapheresis, plasma exchange, and immunoadsorption.
    Jouve T; Marlu R; Naciri Bennani H; Noble J; Chevallier E; Motte L; Imerzoukene F; Malvezzi P; Rostaing L
    J Clin Apher; 2021 Aug; 36(4):574-583. PubMed ID: 33783856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semi-selective immunoadsorption treatment in myasthenia gravis.
    Splendiani G; Passalacqua S; Barbera G; Sturniolo G; Costanzi S; Fulignati P; Casciani CU
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(5):1145-51. PubMed ID: 1457688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
    Wagner S; Janzen RW; Mohs C; Pohlmann S; Klingel R; Grützmacher PW
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoadsorption plasmapheresis for severe generalised myasthenia gravis.
    Ichikawa M; Koh CS; Hata Y; Tohyama M; Tsuno T; Komiyama A
    Arch Dis Child; 1993 Aug; 69(2):236-8. PubMed ID: 8215529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.